Molina Healthcare, Inc.

Molina Healthcare, Inc. (MOH) Market Cap

Molina Healthcare, Inc. has a market capitalization of $9.94B.

Price: $190.86

-1.95 (-1.01%)

Market Cap: 9.94B

NYSE · time unavailable

CEO: Joseph Michael Zubretsky

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2003-07-02

Website: https://www.molinahealthcare.com

Molina Healthcare, Inc. (MOH) - Company Information

Market Cap: 9.94B|Sector: Healthcare

Company Profile

Molina Healthcare, Inc. provides managed health care services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments, Medicaid, Medicare, Marketplace, and Other. As of December 31, 2021, the company served the company served approximately 5.2 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs in 18 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Analyst Sentiment

41%
Underperform

From 18 Active Polls

1Y Forecast: $174.67

▼ -8.5% Potential Upside

Consensus Target Metrics

Low Bound

$124

Median

$165

High Bound

$224

Average

$175

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$174.67
▼ -8.48% Upside
Low Target
$124.00
-35% Risk
Median Target
$165.00
-14% Mid
High Target
$224.00
17% Max
Consensus
Buy
17 / 38 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)9,9446,7988,81510,25716,17617,98516,70619,84716,916
Enterprise Value ($M)8,5775,4318,5179,88815,24016,89515,16217,64414,946
Price to Earnings Ratio (P/E)51.78121.40-13.7732.4615.8615.0916.6415.2214.05
Price/Earnings-to-Growth Ratio (PEG)74.186.312.4410.823.27
Price to Sales Ratio (P/S)0.220.630.770.891.421.611.591.921.71
Price to Book Ratio (P/B)2.391.672.172.453.514.173.724.163.49
Price to Free Cash Flow Ratio (P/FCF)39.626.44-29.68-62.93-47.02107.05-71.0923.68-68.76
Enterprise Value to Sales (EV/Sales)0.500.750.861.331.521.441.711.51
Enterprise Value to EBITDA (EV/EBITDA)13.9044.52-72.1854.3335.3635.1235.4334.3331.14
Debt to Equity Ratio-2.220.970.970.920.770.870.690.530.49

MOH Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$190.86
Intrinsic Value$634.86
Market Alignment
Undervalued by 232.6%relative to calculated intrinsic value
9.00%
Exp: 5%5%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$2.16B
Perpetuity TV Value$40.61B
Discounted TV (PV)$17.15B
TV Weighting %60.1%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MOLINA HEALTHCARE INC (MOH) — Investment Overview

🧩 Business Model Overview

Molina Healthcare is a managed care organization (MCO) that contracts with government payors (primarily Medicaid, and also Medicare-related programs in certain geographies) to administer health benefits for enrolled members. The economic engine is straightforward: Molina receives per-member-per-month (PMPM) revenue based on eligibility and risk-adjustment mechanics, then finances clinical care through a mix of provider payments (capitated, fee-for-service, and value-based arrangements).

The value chain is anchored in (1) state contracting and bid processes, (2) actuarial modeling and risk scoring to price benefits accurately, (3) care delivery operations (utilization management, member engagement, and provider network management), and (4) regulatory and quality reporting that affects payment levels. In MCOs, membership growth and retention depend heavily on contract renewals and performance scoring, which directly links operations to cash flow.

💰 Revenue Streams & Monetisation Model

Revenue is predominantly recurring in nature through PMPM payments, with contractual risk adjustment and quality-linked components that can raise or lower revenue relative to benefit cost. Key monetisation drivers include:

  • PMPM Medicaid/Medicare-related premiums: Core recurring revenue stream; sensitivity to risk coding, eligibility mix, and state-specific benefit structures.
  • Risk adjustment and quality incentives: Payments tied to diagnoses coding, HEDIS measures, and program requirements can materially influence margin stability.
  • Provider cost management: Operating margin depends on whether Molina’s pricing and care management reduce avoidable utilization without impairing quality metrics.

Margin drivers are less about absolute premium growth and more about the discipline of underwriting and the ability to translate clinical operations into lower medical cost trend, while maintaining compliance and quality performance required for sustained contract participation.

🧠 Competitive Advantages & Market Positioning

Molina’s moat is best described as a combination of regulatory barrier and operational switching friction created by contracting, reporting requirements, and network build-out. While enrollment can be mobile, state contracting and performance measurement make provider and member-care ecosystems difficult to replicate quickly.

  • High Barriers to Entry (FDA-equivalent in practice: contracting/quality compliance): Government programs require bid approvals, solvency/financial standards, detailed reporting, and strict compliance. Non-compliance can jeopardize eligibility, making “entry by marketing” ineffective.
  • Quality reporting and risk adjustment know-how: Accurate coding and performance measurement are operational capabilities. Competitors must execute similarly to compete on both price and quality.
  • Integrated care operations for complex populations: Molina’s model is designed for higher-acuity, lower-income and dual-eligible member sets where care management, network enablement, and utilization management materially affect medical loss ratio.

Competitive benchmarking:

  • Centene (CNC): Broad Medicaid exposure and also relies on state contracting depth; both compete on underwriting accuracy and compliance for government programs. Molina’s focus aligns more tightly with targeted Medicaid/Medicare-related geographies and product fit.
  • UnitedHealth Group (UNH) — Optum/UnitedHealthcare: More diversified across commercial and Medicare Advantage. United’s breadth can support cross-subsidisation, while Molina’s concentration can provide sharper operational focus on government programs.
  • Humana (HUM): More Medicare Advantage weighted. Humana competes in a different benefit and risk environment, with Medicare program dynamics and provider arrangements that differ from Medicaid-centric models.

Relative positioning: Molina’s competitive advantage is tied to executing in Medicaid and related government programs where contracting, compliance, and care-management performance are determinative—and where scaling successfully requires proven operational infrastructure rather than brand-driven demand.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth and earnings power in health insurance depend on the interplay between population demographics, program design, and the ability to manage medical cost trend. Key structural drivers include:

  • Program enrollment and demographic tailwinds: Aging demographics and persistent demand for public insurance coverage support steady membership baselines in government-sponsored programs.
  • Value-based care adoption: Incentives and reimbursement models increasingly reward quality outcomes and cost management; MCOs with execution capability can convert care delivery into more stable margins.
  • State contracting cycles and geographic expansion: Successful bidding and renewals can expand footprint. Contract awards reward demonstrated performance, compliance, and actuarial credibility.
  • Risk adjustment sophistication: As diagnosis coding, risk stratification, and program compliance evolve, operational maturity can protect pricing accuracy and margin quality.

⚠ Risk Factors to Monitor

  • Regulatory and contracting risk: Changes in Medicaid/Medicare program rules, reimbursement methodology, eligibility definitions, and quality requirements can alter PMPM economics and required compliance costs.
  • Medical cost trend and utilization shocks: Price and utilization dynamics can diverge from actuarial assumptions, pressuring margin and cash generation.
  • Provider network and reimbursement pressure: Network performance, provider contracting terms, and referral/authorization workflows influence medical costs and quality metrics.
  • Risk adjustment and coding scrutiny: Payment depends on risk scoring and documentation. Errors or compliance failures can lead to revenue pressure and reputational/regulatory consequences.
  • Operational complexity: Scaling across states requires robust systems for claims, quality reporting, care management, and compliance—execution missteps can be costly.

📊 Valuation & Market View

The market typically values managed care insurers using a blend of earnings multiples (commonly EV/EBITDA or P/E depending on analyst preference) and quality-of-earnings frameworks that focus on durability of medical margin and the sustainability of membership and contract performance. Drivers that move valuation expectations include:

  • Medical loss ratio trajectory: Stability versus volatility in medical cost trend.
  • Quality scores and compliance: Ability to sustain incentives and avoid payment reductions.
  • Risk adjustment credibility: Consistency in coding practices and reduced likelihood of payment clawbacks or restatements.
  • Capital and reserve discipline: Insurers with resilient reserve and solvency practices tend to command a higher confidence premium.

Because revenues are contractually recurring but margins can swing with medical and regulatory factors, valuation tends to be more sensitive to earnings quality and execution than to simple topline growth.

🔍 Investment Takeaway

Molina Healthcare’s long-term investment case rests on a defensible position in government-sponsored managed care, supported by regulatory and operational barriers to entry, and the practical switching friction created by state contracting, compliance, and quality/risk-adjustment capabilities. The core question for sustained outperformance is the company’s ability to keep underwriting accuracy and care-management execution aligned with evolving reimbursement and medical cost dynamics while maintaining quality performance that protects PMPM economics.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MOH.

fool.com2026-06-05

Why Molina Healthcare Stock Cruised to a Nearly 10% Gain This Week

Towards the end of the week in particular, investors were hungry for less-risky stocks.

zacks.com2026-06-03

5 HMO Stocks in Focus Amid an Aging U.S. Population, Tech Innovation

Aging demographics, sound Medicare premiums, digital healthcare adoption and increased M&A activity are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

businesswire.com2026-06-02

Molina Healthcare Announces Second Quarter 2026 Earnings Release and Conference Call Dates

LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the second quarter ending June 30, 2026, after the market closes on Wednesday, July 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, July 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 8631129. A telephonic replay of the conference c.

gurufocus.com2026-06-01

Is It Too Late to Buy Molina Healthcare Inc (MOH) After 5.6% Rally? GF Value Says Undervalued

On June 01, 2026, Molina Healthcare Inc (MOH) shares rose 5.6% to a current price of $183.25. This move comes amidst a challenging year, where the stock has see

zacks.com2026-05-28

Should Value Investors Buy Molina Healthcare (MOH) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

businesswire.com2026-05-28

Molina Healthcare Opens One Stop Help Center in Albuquerque to Support Local Families

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Molina Healthcare opens One Stop Help Center in Albuquerque to support local families.

fool.com2026-05-27

Small-Cap Value ETFs: SLYV Tops VBR in One Year Growth, VBR Offers Lower Fees

Expense ratios, diversification, and long-term returns set these two small-cap value ETFs apart-see how their strategies stack up for investors.

zacks.com2026-05-27

Is Molina Healthcare Worth Buying at a Premium 26.83X P/E Valuation?

MOH's premium valuation reflects confidence in growth, acquisitions and cash strength, even as elevated medical costs pressure margins.

gurufocus.com2026-05-26

Molina Healthcare Inc (MOH) Stock Down 4.3% -- Now Undervalued? GF Score: 75/100

On May 26, 2026, Molina Healthcare Inc (MOH) shares fell 4.3% today, closing at $176.20. The stock has experienced a volatile trading range over the past year,

zacks.com2026-05-22

Molina (MOH) Up 3.8% Since Last Earnings Report: Can It Continue?

Molina (MOH) reported earnings 30 days ago. What's next for the stock?

zacks.com2026-05-22

Here's Why Molina (MOH) Could be Great Choice for a Bottom Fisher

Molina (MOH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

247wallst.com2026-05-15

Michael Burry's Latest Buys Include a 6.66% Yielding Pharma Giant and an Oil Stock Up 46% This Year. Here Is Why

Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations.

zacks.com2026-05-12

Are Investors Undervaluing Molina Healthcare (MOH) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

businesswire.com2026-05-12

Molina Healthcare and The MolinaCares Accord Donate $120,000 to Support Programming for Young Adults with Disabilities

LAWRENCE, Mass.--(BUSINESS WIRE)--Molina Healthcare and The MolinaCares Accord donate $120,000 to support programming for young adults with disabilities.

businesswire.com2026-05-11

Molina Healthcare of Michigan and The MolinaCares Accord Donate $130,000 to Libraries for Pilot Programs Addressing Senior Social Isolation

LANSING, Mich.--(BUSINESS WIRE)--Molina Healthcare of Michigan and The MolinaCares Accord donate $130,000 to libraries for pilot programs addressing senior social isolation.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"MOH’s latest quarter (2026-03-31) showed Revenue of $10.80B and Net Income of $14.0M, with EPS of $0.27. YoY, Revenue declined about -3.2% (vs. 2025-03-31) and Net Income fell sharply (from $298M to $14M, ~-95%). QoQ, Revenue decreased about -5.1% (vs. 2025-12-31), while Net Income improved from a prior-quarter loss ($-160M to $14M). Net margin therefore contracted meaningfully: approximately +0.13% in the latest quarter versus ~-1.41% QoQ (still a rebound) and ~2.67% YoY. Cash-flow/dividend support appears limited in this dataset: dividend yield is 0% and payout ratio is 0%, so shareholder returns rely primarily on price performance and any buybacks (not provided here). Balance sheet resilience is mixed-to-positive: total assets rose to $16.39B QoQ, equity was broadly stable around $4.0B, and net debt improved (more negative net debt implies a stronger net-cash position). Total shareholder returns are currently weak, with the stock down -55.2% over 1 year and -21.0% over 6 months. Valuation signals are mixed: current price (~$148.97) sits below the consensus target ($175.64) and near the median target ($158), but the earnings multiple is elevated (P/E ~121 on the latest quarter), reflecting volatility/earnings pressure."

Revenue Growth

Caution

Revenue fell QoQ (~-5.1% from $11.38B to $10.80B) and declined YoY (~-3.2% from $11.15B to $10.80B), indicating a soft demand/trend.

Profitability

Neutral

Net Income improved QoQ (loss of $-160M to profit of $14M), but YoY earnings deteriorated sharply ($298M to $14M). Net margin contracted materially YoY (~2.67% to ~0.13%), and EPS fell from $5.47 to $0.27.

Cash Flow Quality

Caution

Dividend support is absent (0% yield). While net debt improved (stronger net-cash position), the earnings rebound is not yet sustained, limiting confidence in cash-generation quality.

Leverage & Balance Sheet

Neutral

Equity stayed stable (~$4.07B) while total assets increased QoQ. Net debt improved meaningfully (from about -$298M to about -$1.37B), suggesting improved balance-sheet resilience.

Shareholder Returns

Neutral

Total returns are pressured: price performance is sharply negative (-55.2% 1Y) with no dividend yield reported. No buyback data provided to offset price declines.

Analyst Sentiment & Valuation

Caution

Current price (~$148.97) is below consensus ($175.64) and slightly below the median target ($158), but the latest-quarter P/E (~121) is high, reflecting earnings volatility and caution.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Q1 2026 showed solid execution across MOH’s core loss-ratio engine: consolidated MCR 91.1%, Medicaid 92%, Medicare 89.8%, and Marketplace 84% (79.5% adjusted for prior-year risk adjustment/program integrity). Despite modestly favorable medical cost trend vs expectations and confidence in a 5% 2026 Medicaid trend, management reaffirmed full-year guidance (premium revenue ~$42B; adjusted EPS ≥$5), explicitly citing prudence amid prior 2025 volatility and the need for additional time-tested evidence. The key operational update is Medicaid same-store attrition moving to 6% (from 2%) driven by state pressure concentrated in California, Illinois, New York, and Texas—yet management asserted no meaningful continued acuity shift because low/no-utilizer levels are at the lowest since tracking began and leaver/stayer dynamics are near portfolio averages. Capital remains a strength: parent cash ~$213M at quarter-end, dividends supporting expected >$600M by year-end under RBC constraints. The market should focus on May 8 Investor Day and Q2 guidance update for updated assumptions.

AI IconGrowth Catalysts

  • Medicaid medical cost trend holding to a ~5% 2026 assumption; reduced expectation of recurring 2025 acuity shift after redetermination
  • Medicare integrated products transition: MMP members moved into HIDE/FIDE (Duals focus) with early 1Q 2026 start outperforming initial expectations (cautious to confirm via more quarters)
  • Marketplace margin improvement via 2026 pricing actions plus continued shift toward renewal membership (70% of book) and reduced volatile exposure

Business Development

  • Florida CMS (Florida Kids) contract: management cited total run-rate ~$6B revenue program; implementation in full mode; viewed as meaningful embedded earnings contributor over ~2 years
  • CMS final rate notice improvement in Medicare vs preliminary (no named contract, but rate-setting progress discussed)

AI IconFinancial Highlights

  • Reported Q1 2026 adjusted EPS $2.35 vs modest expectations; premium revenue $10.2B; characterized as solid but reaffirmed full-year cautiously
  • Consolidated MCR 91.1% (Q1); Medicaid MCR 92% (Q1); Medicare MCR 89.8% (Q1); Marketplace MCR 84% (Q1) with ~79.5% after adjusting for prior-year risk adjustment and program integrity impacts
  • Medicaid January 1 rate updates met expectations; medical cost trend modestly favorable vs expectation; management expects 5% medical cost trend for 2026
  • Embedded earnings framing: $2.50/share equals 2026 MAPD losses and Florida CMS first-year implementation costs; positive impacts expected for 2027
  • Guidance reaffirmed: full-year 2026 premium revenue ~ $42B; adjusted EPS at least $5; full-year consolidated and segment MCR unchanged

AI IconCapital Funding

  • Q1 subsidiary dividends harvested ~$35M; parent cash balance ~$213M at quarter-end
  • Operating cash flow $1.1B driven by timing of Medicaid and Marketplace government payments
  • Debt end of quarter: 6.1x trailing 12-month EBITDA; debt-to-cap ratio about 48%
  • Parent cash expected to rise to >$600M by year-end based on planned dividends; RBC constraint: dividends only when above RBC target of $300M
  • Days in claims payable: 44 (modestly lower due to quarter-end payment timing)

AI IconStrategy & Ops

  • Medicaid membership attrition guidance increased to 6% in 2026 from prior 2% (same-store membership decline); end-year Medicaid membership forecast ~4.5M
  • Medicaid acuity-shift expectation down: management attributes lack of continued acuity shift to reduced low/no-utilizer share after redetermination (low/no utilizers at lowest level since recorded)
  • Marketplace membership guidance: Q1 paid renewals ended at 305,000; expected year-end ~250,000 with normal attrition; renewal members now represent ~70% of book
  • Operational cost: Q1 adjusted G&A 6.9% largely timing-related; full-year G&A ratio expectation ~6.4%

AI IconMarket Outlook

  • Investor Day on Friday, May 8: 3-year margin and financial outlook through 2029, including updated embedded earnings and longer-term Medicaid membership attrition view
  • Second-quarter results will update full-year 2026 guidance (management reiterated a prudent reaffirmation for Q1 only)
  • Medicaid 2026 assumptions reaffirmed: 92.9% full-year Medicaid MCR including ~4% rate increases and 5% medical cost trend
  • Medicare 2026 guidance: 94% full-year MCR
  • Marketplace 2026 guidance: 85.5% full-year MCR (including normal seasonality)

AI IconRisks & Headwinds

  • Medicaid attrition volatility: incremental membership pressure driven by specific states; attrition now guided higher (6% vs 2%)
  • Uncertainty around network cost inflection volatility seen in late 2025 (management cited volatility as reason to avoid raising guidance in Q1)
  • Marketplace guidance update dependency: management wants to see June risk adjustment/program integrity inputs before truing full-year estimate
  • Medicare integration/product transition period: MAPD drag in 2026 (exiting MAPD for 2027); only 1 quarter of HIDE/FIDE performance so guidance cautious
  • Possible political/regulatory disruption as 2027 pricing cycle approaches (work requirements/biannual redeterminations; mention of disruptive regulatory changes in Marketplace)

Q&A: Analyst Interest

  • Topic: Medicaid attrition driver states and why MLR/acuity impact is limited: Management said incremental pressure is concentrated in California, Illinois, New York, and Texas; California impact tied to undocumented immigrant status members. They argued low/no utilizers are tighter than pre-pandemic and leavers/stayers lever analysis is near portfolio averages, implying acuity shift largely behind them.
  • Topic: Prudent reaffirmation vs remaining unknowns in guidance: Management explained they didn’t raise guidance because Medicaid network cost inflection volatility in late 2025 still drives uncertainty, Marketplace requires June inputs to true up, and Medicare integrated products (HIDE/FIDE) are too early (only one quarter) for time-tested confidence after MAPD drag.
  • Topic: Free cash flow, parent dividends, and capital adequacy (debt-to-cap/RBC): Management emphasized parent cash is what matters versus subsid/dividend constraints. They guided parent cash to >$600M by year-end via expected dividends while keeping RBC above a $300M target threshold; they described debt-to-cap around 47–48% with a typical low-40s sustaining target.

Sentiment: MIXED

Note: This summary was synthesized by AI from the MOH Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MOH.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MOH)

© 2026 Stock Market Info — Molina Healthcare, Inc. (MOH) Financial Profile